Table 2

 Differences in experimental data between treatment with spironolactone and placebo

PlaceboSpironolactonep Value
Data are mean (SD). *p<0.05; **p<0.01.
BNP, β-type natriuretic peptide; BSA, body surface area; HAD, hospital anxiety and depression; HR, heart rate; IVSd, interventricular septum thickness; LVIDd, left ventricular end diastolic diameter; LVM, left ventricular mass; LVMI, left ventricular mass index; LVPWd, left ventricular posterior wall thickness; MLWHF, Minnesota living with heart failure; PIIINP, procollagen III N-terminal peptide; PWV, pulse wave velocity; QT, corrected QT interval; QTd, QT dispersion; QTdc, corrected QT dispersion.
Weight (kg)77.2 (10.2)76.8 (9.70)0.108
SBP (mm Hg)135 (21.8)126 (24.5)0.004**
DBP (mm Hg)77.4 (9.90)72.3 (11.8)0.005**
HR (beats/min)60.0 (12.2)58.8 (7.34)0.475
Sodium (mmol/l)137 (4.20)135 (4.30)0**
Potassium (mmol/l)4.36 (0.41)4.72 (0.41)0**
Urea (mmol/l)6.15 (1.97)7.93 (7.93)0**
Creatinine (μmol/l)91.0 (27.0)101 (33.0)0**
Magnesium (mmol/l)0.89 (0.07)0.87 (0.07)0.044*
Urate (mmol/l)0.37 (0.08)0.37 (0.08)0.695
BNP (pg/ml)48.5 (29.7)36.8 (28.5)0.039*
PIIINP(μg/l)3.767 (1.157)3.156 (1.123)0**
Noradrenaline (pg/ml)769 (361)851 (383)0.114
Adrenaline (pg/ml)82.8 (88.9)94.7 (74.4)0.416
MLWHF score16.2 (15.9)18.8 (18.6)0.044*
Physical score8.31 (7.97)8.86 (8.73)0.47
Emotional score3.31 (4.55)4.02 (5.41)0.227
HAD score7.05 (6.43)8.24 (6.90)0.035*
Anxiety score3.76 (3.71)4.24 (3.75)0.21
Depression score3.31 (3.29)4.00 (3.84)0.023*
6 minute distance (m)472 (81.1)466 (13.9)0.438
PWV (m/s)8.36 (1.27)8.23 (1.23)0.447
Augmentation15.7 (8.91)14.3 (7.04)0.219
Buckberg166 (31.0)170 (32.7)0.389
QT (ms)465 (54.7)447 (56.5)0.009**
QTc (ms)473 (43.1)455 (35.4)0.002**
QTd (ms)84.5 (41.3)72.1 (32.3)0.037*
QTdc (ms)86.0 (39.9)73.4 (30.6)0.032*
BSA (m2)1.93 (0.16)1.92 (0.16)0.393
LVIDd (cm)5.40 (0.86)5.06 (0.94)0.006**
IVSd (cm)1.15 (0.30)1.12 (0.29)0.587
LVPWd (cm)1.04 (0.26)1.11 (0.25)0.25
LVM (g)235 (81.2)215 (71.6)0.022*
LVMI (g/m2)122 (41.0)112 (36.3)0.036*